Differential Impact of Fosaprepitant on Infusion Site Adverse Events Between Cisplatin- and Anthracycline-based Chemotherapy Regimens

作者：Fujii Takeo; Nishimura Naoki^*; Urayama Kevin Y; Kanai Hisako; Ishimaru Hiromasa; Kawano Junko; Takahashi Osamu; Yamauchi Hideko; Yamauchi Teruo

来源：Anticancer Research, 2015, 35(1): 379-383.

• Fosaprepitant
• anthracycline
• cisplatin
• infusion site adverse events

Background: Fosaprepitant may be associated with infusion site adverse events (AEs), and these adverse events possibly vary according to chemotherapy regimen. Patients and Methods: 267 oncology patients who were administered anthracycline- or cisplatin-based regimens were retrospectively studied. Multivariate logistic regression was performed in stratified analyses to evaluate potential regimen-specific effects of fosaprepitant. Results: 41.7% of patients administered fosaprepitant experienced infusion site AEs. On the other hand, only 10.9% of patients administered aprepitant experienced AEs. Multivariate analysis showed a statistically significant overall increased risk of infusion site reaction associated with fosaprepitant (p<0.001), but when evaluated separately according to chemotherapy regimen, this relationship appeared to be largely confined to patients receiving an anthracycline-based regimen (OR=12.95, 95%CI=5.74-29.20). No association was observed among patients on cisplatin-based regimens. A test for interaction was statistically significant (p=0.001). Conclusion: Fosaprepitant is associated with an elevated risk of infusion site reaction in patients receiving anthracyclines.

• 出版日期2015-1